بهبود اختلالات شناختی و خستگی در بیماران استفاده کننده از ناتالیزوماب به دنبال کاهش سطح اوستئوپونتین پلاسمای خون آگوست ۲۰۱۳ The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated Relapsing Multiple Sclerosis. Brain Behav Immun. 2013 Aug 29. pii: S0889-1591(13)00420-0. doi: 10.1016/j.bbi.2013.08.009. [Epub ahead of print] Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. Source Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy. Abstract Objective To investigate the effect of two-years Natalizumab treatment on plasma Osteopontin levels, cognitive performances and fatigue in Relapsing Multiple Sclerosis (RRMS) patients. Methods Forty-nine RRMS patients scheduled for Natalizumab treatment as second-line therapy were enrolled. Plasma samples of twenty-four treatment-naïve RRMS and 22 Healthy Controls (HCs) were used as controls of baseline Osteopontin levels. Plasma Osteopontin levels, using an enzyme-linked immunosorbent assay, cognitive functions using the Brief Repeatable Battery, and fatigue, by the Fatigue Severity Scale(FSS), were assessed at baseline and every 12 months. A global Cognitive Impairment Index (CII) was calculated for each patient. Results Patients scheduled for Natalizumab treatment had higher baseline Osteopontin levels (mean[SD] 65.42[22.20]ng/ml) (p=0.013) than HCs (53.20[12.68]ng/ml), but not different from those in the treatment-naïve RRMS group (67.70[24.23]ng/ml); 30.6% of patients showed a cognitive impairment (failure⩾3 tests) and 47.6% complained fatigue interfering with daily activities(FSS score ⩾ 4.5). A significant decrease of mean Osteopontin levels(p
Posted on: Tue, 03 Sep 2013 18:04:00 +0000
Recently Viewed Topics
© 2015